Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/24 cls

Cubist Pharmaceuticals Inc. (NASDAQ:CBST)

Jefferies

Eun Yang

Price target

Buy

12%

$55.49

RBC Capital Markets

Adnan Butt

Price target

Outperform

Yang raised her target to $64 from $55, saying last week's Markman ruling is "a victory" for Cubist. The U.S. District Court for the District of Delaware issued a ruling interpreting terms used in U.S. Patent Nos. 6,468,967; 8,852,689; 8,058,238; 8,129,342; and RE 39,071 covering Cubist's antibiotic Cubicin daptomycin. The court's interpretation favored Cubist's language on two terms (see B27). Last year, Cubist filed the suit alleging that its patents were infringed by an ANDA submission from Hospira Inc. (NYSE:HSP) for a generic version of Cubicin.